A Study of PLB-002 in Advanced Solid Tumors
This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.
Trial Details
- NCT ID
- NCT07304128
- Phase
- PHASE1
- Sponsor
- Primelink BioTherapeitics(ShenZhen) Limited
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- Patients who meet all of the following criteria will be eligible to participate in the study:
- Patient must have the ability to understand and voluntarily sign a written informed consent form (ICF) and must have signed ICF prior to any study …
- Adults aged 18 years or older.
- Histologically or cytologically confirmed advanced solid tumors, including platinum-resistant ovarian cancer (including fallopian tube and primary …
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →